Coronary angioplasty induced oxidative stress and its relation with metoprolol use and plasma homocysteine levels

Anadolu Kardiyoloji Dergisi

Volumn 6, Issue 4, 2006, Pages 308-313

  Çiçek, Dilek ^a   Tamer, Lülüfer ^a   Pekdemir, Hasan ^a   Cin, V Gökhan ^a   Yildirim, Hatice ^a   Kara, Asuhan Aksoy ^a   Yurtdaş, Mustafa ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

Angioplasty; Homocysteine; Lipid peroxidation; Malondialdehyde; Metoprolol

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; BELOC ZOK; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MALONALDEHYDE; METOPROLOL; NITRATE; UNCLASSIFIED DRUG;

ADULT; AMINO ACID BLOOD LEVEL; ANTIOXIDANT ACTIVITY; ARTICLE; ATRIOVENTRICULAR CONDUCTION; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEART MUSCLE ISCHEMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOGLYCEMIA; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; PROTEIN BLOOD LEVEL; SINUS BRADYCARDIA; STATISTICAL ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; FEMALE; HOMOCYSTEINE; HUMANS; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; METOPROLOL; MIDDLE AGED; MYOCARDIAL ISCHEMIA; REPERFUSION INJURY;

EID: 33846358418     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Ambrosio G, Flaherty JT, Duilio C, Tritto I, Santoro G, Elia PP, et al. Oxygen radicals generated at reflow induce peroxidation of membrane lipids in reperfused hearts. J Clin Invest 1991;87:2056-66.
2. Buffon A, Santini SA, Ramazzotti V, Rigattieri S, Liuzzo G, Biasucci LM, et al. Large, sustained cardiac lipid peroxidation and reduced antioxidant capacity in the coronary circulation after brief episodes of myocardial ischemia. J Am Coll Cardiol 2000;35:633-9.
3. Iuliano L, Pratico D, Greco C, Mangieri E, Scibilia G, FitzGerald GA, et al. Angioplasty increases coronary sinus F2-isoprostone formation: Evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol 2001;37:76-80.
4. Tzivoni D, Medina A, David D, Barzilai Y, Brunel P. Effect of metoprolol in reducing myocardial ischemic threshold during exercise and during daily activity. Am J Cardiol. 1998;81:775-7.
5. Mak IT, Weglicki WB. Protection by beta-blocking agents against free radical-mediated sarcolemmal lipid peroxidation. Circ Res. 1988;63:262-6.
6. Jenkins RR, Del Signore CM, Sauer P, Skelly C. The effect of beta blocking drugs on lipid peroxidation in rat heart in vitro. Lipids. 1992;27:539-42.
7. Liu XK, Engelman RM, Agrawal HR, Das DK. Preservation of membrane phospholipids by propranolol, pindolol, and metoprolol: a novel mechanism of action of beta-blockers. J Mol Cell Cardiol. 1991;23:1091-100.
8. Kalaycioglu S, Sinci V, Imren Y, Öz E. Metoprolol prevents ischemia-reperfusion injury by reducing lipid peroxidation. Jpn Circ J 1999;63:718-21.
9. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-81.
10. Voutilainen S, Morrow JD, Roberts LJ 2nd, Alfthan G, Alho H, Nyyssonen K et al. Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Arterioscler Thromb Vasc Biol. 1999;19:1263-6.
11. Wang G, Mao JM, Wang X, Zhang FC. Effect of homocysteine on plaque formation and oxidative stress in patients with acute coronary syndromes. Chin Med J (Engl). 2004;117:1650-4.
12. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993;84:407-12.
13. Panfilov V, Wahlqvist I, Olsson G. Use of beta-adrenoceptor blockers in patients with congestive heart failure. Cardiovasc Drugs Ther. 1995;9:273-87.
14. Silva JM, Filipe PM, Fernandes AC, Manso CF. Antioxidant effect of drugs used in cardiovascular therapy. Rev Port Cardiol. 1998;17:495-503.
15. Kopff M, Kowalczyk E, Kopff A. Influence of selected cardiological drugs on oxidative status. Pol J Pharmacol. 2004;56:265-9.
16. Roberts MJ, Young IS, Trouton TG, Trimble ER, Khan MM, Webb SW, et al. Transient release of lipid peroxides after coronary artery balloon angioplasty. Lancet 1990;336:143-5.
17. Oostenbrug GS, Mensink RP, Bar FWHM, Hornstra G. Lipid peroxidation-associated oxidative stress during percutaneous transluminal coronary angioplasty in humans. Free Radical. Biol 1997;22:129-36.
18. Cavalca V, Cighetti G, Bamonti F, Loaldi A, Bortone L, Novembrino C, et al. Oxidative stress and homocysteine in coronary artery disease. Clinical Chemistry 2001;47:887-92.
19. Rice-Evans CA. Measurement of total antioxidant activity as a marker of antioxidant status in vivo: procedures and limitations. Free Radic Res 2000;33 Suppl:S59-66.
20. Theres H, Wagner KD, Schulz S, Strube S, Leiterer KP, Romberg D, et al. Oxygen radical system in chronic infracted rat heart: the effect of combined beta blockade and ACE inhibition. J Cardiovasc Pharmacol 2000;35:708-15.
21. Hankey GJ, Eikelboom JW, Ho KW, Bockxmeer FM. Clinical usefulness of plasma homocysteine in vascular disease. Med J Aust 2004;181:314-8.
22. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, et al. Adverse vascular events of homocysteine are modulated by endothelium derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-18.
23. Moselhy SS, Demerdash SH. Plasma homocysteine and oxidative stress in cardiovascular disease. Dis Markers 2003-2004;19:27-31.
24. Schnyder G, Flammer Y, Roffi M, Pin R, Hess OM. Plasma homocysteine levels and late outcome after coronary angioplasty. J Am Coll Cardiol 2002;40:1769-76.
25. Schnyder G, Rouvinez G. Total plasma homocysteine and restenosis after percutaneous coronary angioplasty: current evidence. Ann Med 2003;35:156-63.
26. Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HL. for the GENERATION study group. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting. J Am Coll Cardiol 2002;40:1375-82.
27. Miner SE, Hegele RA, Sparkes J, Teitel JM, Bowman KA, Connelly PW, et al. Homocysteine, lipoprotein (a), and restenosis after percutaneous transluminal coronary angioplasty: a prospective study. Am Heart J 2000;140:272-8.
28. Noguchi N, Nishino K, Niki E. Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation. Biochem Pharmacol 2000;59:1069-76.
29. Santos DJ, Moreno AJ. Inhibition of heart mitochondrial lipid peroxidation by non-toxic concentrations of carvedilol and its analog BM-910228. Biochem Pharmacol. 2001;15;61:155-64.
30. Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995; 16 Suppl F: 38-42.
31. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation. 2002;105:2867-71.